2565657-20-5
Chemical Structure
LSN3353871
- CAS No.: 2565657-20-5
- Formula:C13H18ClNO2
- Molecular Weight:255.74
InChIKey: ZLJPBKYSJWMLRU-FXMYHANSSA-N
SMILES: OC([C@@H](CC1=CC=CC=C1)[C@@H]2CNCC2)=O.Cl
Biological Activity: LSN3353871 is an orally active inhibitor of lipoprotein (a) (Lp (a)) formation, with Kd values of 756 nM (apo (a) KIV8), 605 nM (apo (a) KIV7-8), and 423 nM (apo (a) KIV5-8), respectively, and an IC50 of 1.69 μM against apo (a) KIV5-8. LSN3353871 reduces circulating Lp (a) levels in transgenic mice and cynomolgus monkeys. LSN3353871 can be used in the research of atherosclerotic cardiovascular disease and calcific aortic valve disease[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LSN3353871 | 99.62% | LSN3353871 is an orally active inhibitor of lipoprotein (a) (Lp (a)) formation, with Kd values of 756 nM (apo (a) KIV8), 605 nM (apo (a) KIV7-8), and 423 nM (apo (a) KIV5-8), respectively, and an IC50 of 1.69 μM against apo (a) KIV5-8. LSN3353871 reduces circulating Lp (a) levels in transgenic mice and cynomolgus monkeys. LSN3353871 can be used in the research of atherosclerotic cardiovascular disease and calcific aortic valve disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
